Long-acting injectable treatment for HIV in Belgium
Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium
This study is looking to see how well people with HIV feel about and respond to a long-acting injectable treatment they’ve received.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Belgian Research on AIDS and HIV Consortium Academic / other |
| Locations | 1 site (Brussels) |
| Trial ID | NCT06424964 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to evaluate the patient-reported outcomes and clinical results of long-acting injectable cabotegravir/rilpivirine for HIV treatment. It will involve multiple centers and focus on assessing patient satisfaction and perceptions regarding this treatment. Participants will include HIV-1 patients who have received at least one dose of the medication between specified dates. The study will also collect demographic and health-related data to better understand the characteristics of the participants.
Who should consider this trial
Good fit: Ideal candidates are HIV-1 patients aged 18 and older who have received at least one dose of the treatment.
Not a fit: Patients who have not received the long-acting injectable cabotegravir/rilpivirine will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of patient satisfaction and outcomes with long-acting injectable HIV treatments.
How similar studies have performed: While this approach is observational, similar studies on long-acting injectable treatments have shown promising results in improving patient adherence and satisfaction.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI CAB/RPV between September 1, 2021, and March 31, 2024.
Where this trial is running
Brussels
- Saint-Pierre University Hospital — Brussels, Belgium (Recruiting)
Study contacts
- Principal investigator: Stéphane De Wit, MD/PhD — Belgian Research on AIDS & HIV Consortium
- Study coordinator: Rakan Nasreddine, MD
- Email: rakan.nasreddine@stpierre-bru.be
- Phone: +32 2 535 4130
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.